Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pricing Debate

Set Alert for Pricing Debate

Provider Consortium Will Try 'DIY' Solution To Generic Shortages, Pricing

Four health care systems representing 280 hospitals, with input from the US Department of Veterans Affairs, plan to make and sell their own generic drugs, focusing on those vitally needed by hospitals, with "appropriate" pricing.

Generic Drugs Pricing Debate Strategy

Latest From Pricing Debate

Trump's Drug Pricing Plans On Slow Walk? HHS To Solicit Comment On Policies

No big policy implementation expected to be announced during president's speech planned for next week. HHS will continue to gather feedback on various approaches to lowering drug pricing.

Pricing Debate Medicare

Maryland 'Price Gouging' Law's Loss In Court Could Derail Similar Legislation

States will likely need to craft different legislation on Rx prices after Fourth Circuit rules Maryland's statute violates Commerce Clause because it regulates transactions outside state.
Pricing Debate Legal Issues

Generics Firms Swap Tendering For Price Cuts In Canada

Generic drug manufacturers in Canada have agreed to price cuts of up to 40% to stave off tendering.
Pricing Strategies Pricing Debate

ICER To Open Cost Effectiveness Models To Drug Firms During Review Process

Institute for Clinical and Economic Review launching pilot program that allows drug assessment models  to be inspected, but not manipulated, by manufacturers.
Pricing Debate Policy

How Is Pharma Spending Tax Savings? Not On Drug Pricing, Sen. Booker Says

As pharma invests its bounty from last year's tax reform in stock buybacks, capital improvements and other investments, Sen. Cory Booker issues a report suggesting companies should lower drug prices instead, but does not offer recommendations for how that might be done.

Business Strategies Pricing Debate

PBM Mergers: Vertical Integration Is Cool – But Don’t Overlook Horizontal Consolidation In Part D

It is hard not to get caught up in the excitement of reinventing health care deliver amid the wave of retail, PBM and insurer merger agreements and rumors. But there is an immediate impact that might be overlooked: the Medicare Part D market is going to be much more consolidated.

Pharmacy Benefit Management Pricing Strategies

Lilly's Prices After Concessions Rise 6% In 2017, While Merck's Net Prices Decline

Price transparency reports from the big pharmas also show continued increases in price concessions in 2017, but a slow-down in list price increases.

Pricing Debate Pricing Strategies

Lilly's Prices After Concessions Rise 6% In 2017, While Merck's Net Prices Decline

Price transparency reports from the big pharmas also show continued increases in price concessions in 2017, but a slow-down in list price increases.

Pricing Debate Pricing Strategies

Remove QALYs From Orphan HTA Assessments, Says Irish Bill

An Irish private members bill aims to exempt orphan drugs from health technology appraisals based on incremental cost-effectiveness ratio thresholds and quality adjusted life years.

Cost Effectiveness Government Payers
See All
UsernamePublicRestriction

Register